Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer
Authors:
Kara N. Maxwell, Danielle Soucier-Ernst, Emin Tahirovic, Andrea B. Troxel, Candace Clark, Michael Feldman, Christopher Colameco, Bijal Kakrecha, Melissa Langer, David Lieberman, Jennifer J. D. Morrissette, Matt R. Paul, Tien-chi Pan, Stephanie Yee, Natalie Shih, Erica Carpenter, Lewis A. Chodosh, Angela DeMichele
In the original publication of the article, the labelling for the legend of Fig. 3a was erroneously switched. The corrected Fig. 3 is given in this erratum.
Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer
Authors
Kara N. Maxwell Danielle Soucier-Ernst Emin Tahirovic Andrea B. Troxel Candace Clark Michael Feldman Christopher Colameco Bijal Kakrecha Melissa Langer David Lieberman Jennifer J. D. Morrissette Matt R. Paul Tien-chi Pan Stephanie Yee Natalie Shih Erica Carpenter Lewis A. Chodosh Angela DeMichele
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.